![Top 20 global biopharmaceutical companies by market capitalization (quarter ended March 31, 2022), presented by GlobalData - GlobalData Top 20 global biopharmaceutical companies by market capitalization (quarter ended March 31, 2022), presented by GlobalData - GlobalData](https://eu.vocuspr.com/Publish/3434416/vcsPRAsset_3434416_152867_e4c0333c-75ea-4f1c-980f-89a5fd811bc4_0.png)
Top 20 global biopharmaceutical companies by market capitalization (quarter ended March 31, 2022), presented by GlobalData - GlobalData
![mRNA IP and Competitive Landscape: 2021 in Review – Part I, Update on Moderna, BioNTech, and CureVac mRNA IP and Competitive Landscape: 2021 in Review – Part I, Update on Moderna, BioNTech, and CureVac](https://ipwatchdog.com/wp-content/uploads/2021/12/2021_1-scaled.jpg)
mRNA IP and Competitive Landscape: 2021 in Review – Part I, Update on Moderna, BioNTech, and CureVac
Buy Moderna and BioNTech Stock. Both Pharmas Have Strong Drug Pipelines and Plenty of Cash. - Barrons
![Top 20 biopharmaceutical companies hold their spot despite market cap drop in Q1 2022 - Pharmaceutical Technology Top 20 biopharmaceutical companies hold their spot despite market cap drop in Q1 2022 - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/05/globsl.png)
Top 20 biopharmaceutical companies hold their spot despite market cap drop in Q1 2022 - Pharmaceutical Technology
![Small-cap stocks jump ahead of larger peers as US limps toward economic recovery | S&P Global Market Intelligence Small-cap stocks jump ahead of larger peers as US limps toward economic recovery | S&P Global Market Intelligence](https://www.snl.com/articles/407090997.png)